NCT05888402View on ClinicalTrials.gov

Induction Chemotherapy and Toripalimab Followed by Chemoradiotherapy for Large-volume Local Advanced NSCLC

PHASE2RecruitingINTERVENTIONAL
Enrollment

50

Participants

Timeline

Start Date

May 1, 2023

Primary Completion Date

June 30, 2025

Study Completion Date

December 31, 2025

Conditions
Local Advanced Non-small Cell Lung Cancer
Interventions
DRUG

Toripalimab

Two cycles of induction Toripalimab (240mg every 3 weeks) plus platinum-based doublet chemotherapy as induction chemoimmunotherapy.

RADIATION

Concurrent chemoradiation therapy and consolidation immunotherapy

Thoracic radiation therapy (54-66Gy/25-33F/5-7week), concurrently with platinum-based doublet chemotherapy, followed by consolidation Toripalimab (240mg every 3 weeks) as consolidation immunotherapy for up to 12 months.

Trial Locations (1)

100021

RECRUITING

Chinese Academy of Medical Science and Peking Union Medical College, Beijing

All Listed Sponsors
collaborator

Shanghai Junshi Bioscience Co., Ltd.

OTHER

lead

Cancer Institute and Hospital, Chinese Academy of Medical Sciences

OTHER